Original research article BACKGROUND: Type 2 diabetes mellitus (DM) and obesity independently increase the risk of heart failure by incompletely understood mechanisms. We propose that hyperinsulinemia might promote adverse consequences in the hearts of subjects with type-2 DM and obesity.
c ardiovascular disease remains the greatest unmet challenge in reducing mortality in subjects with type 2 diabetes mellitus (DM) and the metabolic syndrome. 1 Heart failure risk remains substantially elevated in (DM) even after adjusting for traditional risk factors such as ischemic heart disease and hypertension. 2 Indeed, the term diabetic cardiomyopathy has been used to describe intrinsic pathophysiological mechanisms in cardiomyocytes, which are exacerbated by DM, that directly lead to cardiac dysfunction or may exacerbate cardiac dysfunction in the face of stressors such as cardiac ischemia or hypertrophy. 2, 3 Multiple mechanisms have been suggested, including altered substrate metabolism, mitochondrial dysfunction, and altered calcium signaling. 4 Altered myocardial insulin signaling has emerged as a potential pathophysiological mechanism. 5, 6 The specific mechanisms linking insulin resistance and heart failure have been challenging to unravel given the complex interactions between insulin signaling pathways, such as Akt signaling, chronic activation of which may accelerate ventricular remodeling, [7] [8] [9] and impaired activation of FOXO proteins, a hallmark of cellular insulin resistance, which may also exacerbate heart failure in insulin-resistant states. [10] [11] [12] Moreover, in type 2 DM, hyperinsulinemia has been associated with depressed adrenergic signaling, which may lead to decreased contractility despite elevated catecholamine levels presumably because of either dysfunctional calcium handling within cardiomyocytes or catecholamine-induced β-adrenergic receptor (βAR) desensitization. [13] [14] [15] [16] Human studies have suggested that insulin receptor (IR)-mediated signaling is enhanced in heart failure. 9 We also recently demonstrated that reducing IR signaling in cardiomyocytes attenuated left ventricular (LV) dysfunction and adverse LV remodeling after transverse aortic constriction. 7 A novel mechanism by which hyperinsulinemia might impair myocardial contractility is by inhibition of adrenergic signaling. We recently provided direct molecular evidence for an inhibitory effect of insulin signaling on β-adrenergic responsiveness in the heart that was mediated by β 2 AR signaling pathways. 17 It is interesting to note that some clinical trials have suggested that insulin treatment or drugs that may raise circulating insulin concentrations might increase mortality or hospitalization rates in patients with heart failure. [18] [19] [20] [21] Although β blockade with either β-1 selective agents, such as metoprolol 22 or β 1 AR, and β 2 AR nonselective agents, such as carvedilol, 23 reduces mortality in patients with DM and heart failure, the mortality reduction benefit is attenuated relative to nondiabetics, and some trials suggest that agents with β 2 AR-blocking properties could be superior. 24 Therefore, additional mechanistic studies are required to elucidate the complex interactions between insulin and β-adrenergic signaling that may increase heart failure risk in DM.
Biochemically, IRs and βARs induce heterologous signal transduction pathways leading to different cellular processes. IRs, a member of the large receptor tyrosine kinase family, phosphorylates insulin receptor substrate, leading to Akt and extracellular regulated protein kinase (ERK) activation. [25] [26] [27] Ligand binding to βARs, which are prototypical members of the G protein-coupled receptor superfamily, induces cAMP-dependent protein kinase A (PKA) activation. [28] [29] [30] [31] Studies in adipocytes and liver cells have suggested that insulin and adrenergic stimulation act reciprocally to blunt each other's signaling. Recently, we have shown that IRs and β 2 ARs form a membrane receptor complex to coordinate signal transduction induced by insulin and catecholamines in the heart. 17, 32 The mechanism and consequence of cross-talk between IRs and βARs appears to be cell-and tissue-specific and remains incompletely understood in cardiac tissue. In particular, little is known about how IR signaling may affect βAR signaling in the myocardium to modulate cardiac function in clinically relevant states, such as DM and heart failure.
clinical Perspective
What is new?
• Hyperinsulinemia, which characterizes insulinresistant states, synergistically interacts with β 2 -adrenergic receptor signaling pathways by induction of the phosphodiesterase phosphodiesterase 4D that degrades cAMP. This pathway is activated in human hearts in diabetes mellitus.
• Hyperinsulinemia-induced β 2 -adrenergic receptor signaling pathway inhibits cardiac function and promotes structural injury.
• In a mouse model of obesity and type 2 diabetes mellitus, myocardial injury and dysfunction can be reversed by pharmacologically inhibiting GRK2 signaling with the drug Paroxetine (currently used clinically as an antidepressant) or by inhibiting β 2 -adrenergic receptor signaling with Carvedilol independently of changes in systemic metabolic parameters (ie, hyperglycemia and hyperinsulinemia).
What are the clinical implications?
• This is the first demonstration that targeting this novel insulin-β 2 -adrenergic receptor pathway therapeutically may materially prevent diabetes mellitusassociated heart failure, which remains a clinically intractable problem that may be exacerbated after treatment with most existing diabetes mellitus therapeutics, particularly those that cause hyperinsulinemia.
• This study has significant implications for the use of β-blockers in the management of diabetes mellitus-associated heart failure and opens up a new therapeutic role for an existing drug that could be repurposed to treat heart failure in diabetes mellitus.
ORIGINAL RESEARCH ARTICLE

75
We hypothesized that DM-associated heart failure is caused, in part, by decreased myocardial contractility that is mediated by insulin-induced depression of βAR signaling in cardiomyocytes, which decreases cAMP/ PKA activities and substrate phosphorylation, which are required to sustain cardiac contractility. In the present study, we reveal that hyperinsulinemia selectively induces cardiac expression of phosphodiesterase 4D (PD-E4D), an enzyme that is critically involved in regulating cAMP-PKA activity in cardiac adrenergic signaling and function. 33, 34 We show that hyperinsulinemia-induced PD-E4D expression impairs adrenergic regulation and promotes cardiac dysfunction in a diabetic model induced by high-fat diet (HFD) feeding and identify the molecular pathways that mediate this. We also demonstrate that pharmacological or genetic inhibition of these pathways can effectively prevent or treat obesity or DM-related heart failure.
MethODs experimental animals and in Vivo treatment
The animal care and experimental protocols followed US National Institutes of Health guidelines and were approved by the Institutional Animal Care and Use Committees of the University of California at Davis, the University of Utah, and the Carver College of Medicine of the University of Iowa. C57BL/6J mice were purchased from Charles River. Six-week-old male wild-type, β 2 AR global knockout (β 2 KO), and β-arrestin2 global knockout (β-arr2 KO) mice were randomly assigned to 2 groups fed ad libitum with either a low-fat diet or a matched HFD (Research Diets Inc.) for 6 months (n=26). The low-fat diet was D12450J (3.85 kcal/g; 10% of calories from fat, 20% of calories from protein, and 70% of calories from carbohydrate), and the HFD was D12492 (5.24 kcal/g; 60% of calories from fat, 20% of calories from protein, and 20% of calories from carbohydrate). Blood glucose levels were measured after a fast of 6 hours. Cardiac function was assessed at 4 weekly intervals starting after 8 weeks on on the HFD until 24-weeks, by echocardiography under isoflurane anesthesia. Mice were subjected to intraperitoneal glucose tolerance testing after each echocardiography study. Echocardiography was performed with a Vevo 2100 imaging system from VisualSonics with a 22-to 55-MHz MS550D transducer.
Primary adult cardiomyocyte isolation and culture
The isolation of adult cardiomyocytes was carried out as described previously. 17 Freshly isolated adult cardiomyocytes were loaded with Fluo-4 am (5 μM; Molecular Probes) for 30 minutes before measuring calcium transients and contractility as described. 32 
statistical analysis
All data are expressed as mean±SEM. All statistical analysis was performed using the SPSS statistical software, version 22 .0. The sample size for each group is shown in the figure legends or in the online-only Data Supplement tables. The in vitro studies were done with at least 3 sets of independent experiments. All data were normally distributed. The differences between 2 groups were then evaluated by 2-tailed Student's t test, and the comparisons of multiple groups were performed with either 1-or 2-way analysis of variance, followed by post hoc Tukey's test. For the time course animal studies, data were analyzed with repeated measures analysis of variance. P<0.05 was defined as statistically significant.
Extended methods can be found in the online-only Data Supplement materials.
results
We examined whether DM is associated with modification of adrenergic signaling in human hearts. In right atrial appendage tissues from patients with type 2 DM or nondiabetics obtained at the time of coronary artery bypass surgery, PDE, and G-protein-coupled receptor kinase 2 (GRK2) were significantly increased relative to patients without DM ( Figure 1A ). We then examined a murine model of HFD feeding that develops obesity, hyperglycemia, and hyperinsulinemia (online-only Data Supplement Figure IA and IB). After 6 months of HFD feeding, these animals developed cardiac hypertrophy and fibrosis when compared with normal chow (NC) controls; they also displayed a small but significant increase in apoptosis in myocardium (online-only Data Supplement Figure IIA and IIB). In concordance with data from human tissues, both mRNA and protein levels of a PDE4 family gene PDE4D were specifically induced in HFD hearts relative to those fed with NC ( Figure 1B and  1C) . In contrast, the other PDE isoforms were not altered ( Figure 1C ). In isolated adult ventricular myocytes (AVMs), insulin but not glucose, induced PDE4D protein levels ( Figure 1D ), suggesting that insulin-induced signaling may modulate PDE4D expression in HFD hearts. We also examined insulin-signaling pathways in HFD hearts. The expression of IR and IRS2 were reduced in HFD hearts relative to those fed with NC ( Figure 1E and online-only Data Supplement Figure IC) . Accordingly, compared with isolated myocytes from NC hearts, myocytes from HFD hearts displayed a blunted response to insulin stimulation (online-only Data Supplement Figure  ID) . It is important to note that basal ERK and Akt signaling and downstream S6K1 and GSK3 phosphorylation were significantly elevated in HFD hearts relative to those fed with NC ( Figure 1E ). These data suggest that, despite insulin resistance, ambient hyperinsulinemia may activate the remaining IRs to promote downstream signaling that might regulate gene expression.
PDE4D plays an essential role in controlling cAMP levels in hearts by hydrolysis of cyclic nucleotides. In HFD hearts with elevated PDE4D expression, cAMP levels and cAMP-dependent PKA phosphorylation of substrates such as phospholamban (PLB) and troponin I that are involved in cardiac contractility were reduced (Figure 2A and 2B). As a consequence, HFD mice developed timedependent diastolic and systolic cardiac dysfunction (Figure 2C and online-only Data Supplement Table I ). In addition, HFD mice displayed reduced PKA phosphorylation of PLB and cardiac reserve in response to β-adrenergic stimulation ( Figure 2D and 2E). Taken together, these data link hyperinsulinemia with PDE4D induction, im- A, Right atrial appendage tissues from patients with diabetes mellitus display increased phosphodiesterase 4D (PDE4D) protein levels relative to patients without diabetes mellitus (n=6). B and C, Six months of high-fat diet (HFD) increases protein and mRNA levels of PDE4D in mouse hearts (n=12). D, Overnight treatment with insulin (100 nmol/L) but not glucose (400 mg/dL) increases PDE4D expression levels in mouse adult ventricle myocytes (AVMs) (n=6). 
P<0
.001 by student t test between paired groups). AKT indicates protein kinase B; β 1 AR, β1 adrenergic receptor; βarr2, β arrestin 2; Con, control; DM, diabetes mellitus; GI, inhibitory G protein; Glu, glucose; GRK2, G protein-coupled receptor kinase 2; HFD, high fat diet; Ins, insulin; IR, insulin receptor; NC, normal chow; NDM, nondiabetes mellitus; pERK, phosphorylated extracellular signal-regulated kinase; PLB, phospholamban; TnI, troponin I; and WT, wild type. paired inotropic signaling to adrenergic stimulation, and diastolic and systolic dysfunction in murine hearts.
We therefore hypothesized that increased cAMP degradation resulting from increased PDE4D expression in HFD hearts will impair cardiac contractile function in response to adrenergic stimulation. In isolated naïve AVMs, 12-hour incubation with insulin significantly reduced adrenergic (isoproterenol)-induced cAMP levels, which was rescued by a specific PDE4 inhibitor rolipram ( Figure 3A) . In AVMs isolated from HFD hearts, PKA phosphorylation of both PLB and troponin I in response to adrenergic stimulation was significantly impaired relative to those from NC controls ( Figure 3B ). In parallel, calcium transients and contractile shortening in response to adrenergic stimulation were also impaired in AVMs from HFD hearts ( Figure 3C ). The PDE4 inhibitor Rolipram rescued PKA phosphorylation of PLB, calcium transients, and contractile shortening in HFD myocytes ( Figure 3B and 3C ). These data suggest that hyperinsulinemia-induced PDE4D expression contributes to impaired inotropic signaling in cardiomyocytes.
IR activation promotes 2 major signaling cascades that modulate cellular responses, namely, ERK and Akt. Both ERK and Akt phosphorylation were elevated in HFD hearts. We examined which signaling branch is involved in the induction of PDE4D expression. In isolated AVMs, inhibition of ERK but not Akt completely blocked insulin-induced induction of PDE4D ( Figure 4A ). We then sought to map the signaling nodes required for ERK activation and PDE4D induction in HFD hearts with strategies in vivo and in cultured cardiomyocytes. We first examined PDE4D expression in the hearts of mice with cardiomyocyte-restricted deletion of IR. 25 As shown in Figure 4B , PDE4D expression was reduced by 50% in cardiomyocyte-restricted deletion of IR mice fed a NC diet and remained repressed after HFD ( Figure 4B and 4C). Inhibition of IRS but not GRB2 significantly blocked insulin-induced ERK activation and PDE4D induction in isolated AVMs ( Figure 4D and 4E). These data suggest that in this experimental context, ERK activity induced by insulin might be independent of the classical IRS growth factor receptor-bound protein 2 (GRB2)-SOS cascade.
To further explore the underlying mechanisms by which insulin induces PDE4D, we examined the recently characterized membrane IR-β 2 AR complex, by which 
.001 by repeated measures analysis of variance (ANOVA). D and E, After 6 month of HFD, mouse hearts display reduced PKA phosphorylation of PLB (S16, n=6) and contractile response to β-adrenergic stimulation (ISO, 0.2 mg/kg in vivo, n=12; **P<0.01 and ***P<0.001 by 1-way ANOVA followed by post hoc Tukey's test). cAMP indicates cyclic adenosine monophosphate; E'/A', the ratio of the early (E) to late (A) ventricular filling velocities; HFD, high fat diet; ISO, isoproterenol; IVRT, isovolumic relaxation time; NC, normal chow; PLB, phospholamban; pPLB, phosphorylated phospholamban; pTnI, phosphorylated troponin I; TnI, troponin I; and WT, wild type. 's test) . B and C, HFD leads to reduced protein kinase A (PKA) phosphorylation of phospholamban (PLB) (S16) and troponin I (TnI) (S23/24), calcium signaling, and contractility in mouse AVMs in response to β-adrenergic stimulation (ISO, 100 nmol/L for AVM stimulation, n=6), which are rescued by the PDE4 inhibitor rolipram (100 nmol/L; **P<0.01 and ***P<0.001 by 1-way ANOVA followed by post hoc Tukey's test). cAMP indicates cyclic adenosine monophosphate; CFP, cyan fluorescent protein; Cilo, cilostamide; Con, control; HFD, high fat diet; Ins, insulin; ISO, isoproterenol; NC, normal chow; PLB, phospholamban; pPLB, phosphorylated phospholamban; pTnI, phosphorylated troponin I; Roli, rolipram; TnI, troponin I; and YFP, yellow fluorescent protein.
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79 stimulation of the IR leads to an IRS-dependent and GRK2-mediated phosphorylation of the β 2 AR. 17, 32 We hypothesized that the insulin-induced and GRK2-phosphorylated β 2 AR might promote arrestin-dependent ERK activation. 35 Indeed, β 2 AR formed a complex with β-arr2 and ERK in cardiac myocytes after insulin stimulation; the receptorbound ERK displayed increased activity (online-only Data Supplement Figure IIIA) . Deletion of either β 2 AR or β-arr2 almost completely blocked insulin-induced ERK activation and PDE4D induction ( Figure 5A and 5B). In contrast, deletion of β 1 AR did not affect insulin-induced ERK activation and PDE4D induction (online-only Data Supplement Figure IIIB ). Meanwhile, a clinical nonselective β-blocker carvedilol with arrestin-biased properties and a neutral nonselective β-blocker timolol both attenuated insulininduced ERK activation and PDE4D induction (onlineonly Data Supplement Figure IIIC) . Moreover, in β 2 AR-KO AVMs, reintroduction of wild-type but not mutant β 2 AR lacking the GRK phosphorylation sites restored insulininduced ERK activation and PDE4D induction ( Figure 5C ). Furthermore, a selective serotonin reuptake inhibitor, paroxetine, which also acts as a specific GRK2 inhibitor, A, Insulin (100 nmol/L) induces PDE4D expression in mouse adult ventricle myocytes (AVMs) that is dependent on extracellular regulated protein kinase (ERK) (T202/Y204) but not Akt (S473) signaling (n=3). B and C, Decreased PDE4D content in the hearts of mice with cardiomyocyte-restricted deletion of IR (CIRKO) on normal chow or after 36 weeks of a 45% high-fat diet (HFD) (n=6). D and E, Insulin-induced ERK activation and PDE4D expression in mouse AVMs is IRS-dependent but growth factor receptor-bound protein 2 (GRB2)-independent (n=3). PQ401 is an IRS inhibitor, and actinomycin D (ActD) is an inhibitor of GRB2 (*P<0.05, **P<0.01, and ***P<0.001 by 1-way analysis of variance [ANOVA] followed by post hoc Tukey's test). ActD indicates actinomyosin D; AKT, protein kinase B; AVMs, adult ventricle myocytes; CIRKO, cardiac insulin receptor knockout; Con, control; ERK, extracellular signal-regulated kinase; GAPDH, Glyceraldehyde 3-phosphate dehydrogenase; HFD, high fat diet; Ins, insulin; NC, normal chow; pERK, phosphorylated extracellular signal-regulated kinase; and WT, wild type. A, Deletion of β 2 AR prevented HFD-induced activation of extracellular regulated protein kinase (ERK) (T202/Y204) and Akt (S473) and PDE4D induction in mouse hearts (n=12). B, Deletion of β 2 AR normalizes protein kinase A (PKA) phosphorylation of phospholamban (PLB) (S16) and troponin I (TnI) (S23/24), the ratio of serca2/PLB in mouse hearts and attenuates the induction of growth factor receptor-bound protein 2 (GRK2) (n=12). C, Deletion of β-arr2 prevents HFD-induced activation of ERK and Akt and PDE4D induction in mouse hearts (n=12). D, Deletion of β-arr2 normalizes PKA phosphorylation of PLB (S16) and TnI (S23/24), the ratio of serca2/PLB in mouse hearts, and prevents the induction of GRK2 (n=12; *P<0.05 and **P<0.01 by 1-way analysis of variance [ANOVA] followed by post hoc Tukey's test). AKT indicates protein kinase B; β1AR, β1 adrenergic (Continued ) significantly blocked insulin-induced ERK activation and PDE4D induction ( Figure 5D ), whereas another selective serotonin reuptake inhibitor, fluoxetine, did not affect insulin-induced ERK activation and PDE4D induction (onlineonly Data Supplement Figure 3D ). These data support the existence of a novel IR/IRS-induced and GRK-mediated transactivation of a β 2 AR-β-arr2-ERK signaling cascade, which is the primary mediator of insulin-induced ERK activation in cardiomyocytes and is also necessary for insulin-induction of PDE4D expression ( Figure 5E ). To determine whether this novel IR signaling cascade impairs the activation of signaling mediators of excitationcontraction (EC) coupling and contributes to cardiac dysfunction associated with DM, mice with germline deletion of either β 2 AR or β-arr2 gene were fed with HFD or NC. On the HFD, these mutant mice still became obese and diabetic (online-only Data Supplement Figure IVA Figure 6B and 6D) . Deletion of either gene also normalized the ratio of serca2 to PLB, which was reduced in wild-type HFD hearts ( Figure 6B and 6D) . Accordingly, deletion of either gene blocked the decrease in cAMP levels in HFD hearts ( Figure 7A ). Moreover, deletion of either β 2 AR or β-arr2 genes significantly ameliorated cardiac dysfunction induced by HFD feeding ( Figure 7B ). In AVMs from HFD hearts lacking the β 2 AR or β-arr2 gene, calcium transients and contractile shortening in response to adrenergic stimulation were normal relative to those from NC hearts ( Figure 7C and 7D) . The PDE4 inhibitor rolipram did not further enhance calcium transients and contractile shortening in HFD myocytes ( Figure 7C and 7D ). These data suggest that deletion of either β 2 AR or β-arr2 significantly restored contractility in cardiomyocytes and ameliorated cardiac dysfunction in hearts.
This novel IR-induced transactivation of the β 2 AR-β-arr2-ERK signaling module presents new therapeutic opportunities to treat/prevent cardiac dysfunction associated with DM. We therefore tested whether blocking GRK2-mediated transactivation of the β 2 AR would be effective in attenuating cardiac dysfunction induced by HFD. Animals fed with HFD for 4 months displayed cardiac dysfunction ( Figure 2C ); mice were then subjected to 1-month therapy with vehicle, the GRK2-specific inhibitor paroxetine that was recently shown to be effective in treating myocardial infarction-induced heart failure, 37 or carvedilol, the clinically effective nonselective β-blocker that blocks both β 1 AR and β 2 AR. Both paroxetine and carvedilol treatments attenuated ERK and Akt activities and PDE4D induction in hearts relative to animals treated with vehicle alone, with paroxetine treatment being more effective ( Figure 8A ). Both treatments normalized cAMP levels and PKA phosphorylation of PLB and troponin I in HFD hearts relative to vehicle-treated mice (Figure 8B and 8C ) and normalized the ratio of serca2 and PLB ( Figure 8C ). Paroxetine and carvedilol did not alter fasting glucose concentrations but partially improved glucose tolerance, although hyperinsulinemia persisted (online-only Data Supplement Figure VIIA and VIIB). Despite modest effects on systemic metabolic homeostasis, cardiac fibrosis and apoptosis were largely reversed in HFD mice, although cardiac hypertrophy persisted (online-only Data Supplement Figure VIIIA through VIIIC) .
It is important to note that paroxetine and carvedilol significantly improved cardiac dysfunction compared with HFD mice treated with vehicle ( Figure 8D and online-only Data Supplement Table III) .
DiscussiOn
Hyperinsulinemia is an independent risk factor for ischemic cardiac disease and predicts coronary atherosclerosis. 38, 39 Moreover, hyperinsulinemia has been correlated with depressed adrenergic signaling, which may contribute to systolic and diastolic dysfunction in diabetes, despite elevated catecholamine levels, presumably because of either dysfunctional calcium handling within cardiomyocytes or catecholamine-induced βAR down-regulation. [13] [14] [15] [16] The present study demonstrates that hyperinsulinemia directly impairs cardiac function by depressing cardiomyocyte adrenergic signaling. We describe a novel mechanism, whereby hyperinsulinemia remodels adrenergic signal transduction pathways by selectively increasing the expression of PDE4D but not of βARs. Hyperinsulinemia drives a novel IR signaling cascade by IRS-and GRK2-dependent transactivation of a β 2 AR-arr-ERK pathway to promote expression of the PDE4D gene. The elevated PDE4D enzyme reduces cAMP activity and PKA phosphorylation of its substrates that may contribute to reduced myocyte calcium cycling and contractile shortening, and systolic and diastolic cardiac dysfunction. Pharmacological inhibition of GRK2 or the β 2 AR can effectively reverse cardiac dysfunction induced by HFD.
Mechanistically, IR and β 2 AR form a membrane complex in cardiomyocytes. 17, 32 Activation of IR promotes Figure 6 continued. receptor; β 2 KO, β2 adrenergic receptor knockout; βarr2, β arrestin 2; ERK, extracellular signal-regulated kinase; GRK2, G protein-coupled receptor kinase 2; HFD, high fat diet; NC, normal chow; pERK, phosphorylated extracellular signal-regulated kinase; PLB, phospholamban; pPLB, phosphorylated phospholamban; pTnI, phosphorylated troponin I; TnI, troponin I; and WT, wild type. IRS and GRK2-mediated phosphorylation of the β 2 AR, 17, 32 which leads to arrestin-dependent ERK activation (Figure 4) . Therefore, IR induces arrestin-biased transactivation of the β 2 AR in a GRK2 phosphorylation-dependent manner. It is surprising that this new signaling branch is the major mediator of ERK activity induced by insulin, whereas the classic IRS-GRB2-SOS axis appears to play a minor role in promoting insulin-induced ERK activation in the heart ( Figure 5 ). Moreover, our data suggest that only the β 2 AR-dependent activation of ERK is necessary for gene expression of PDE4 in cardiomyocytes and hearts, suggesting that insulin signaling may activate distinct pools of ERK, leading to diverse cellular responses. Insulin-induced transactivation of the β 2 AR may also play a role in Akt activation, which could promote cardiac hypertrophy independently of the ERK-PDE4D axis. Hyperinsulinemia and hyperglycemia persist in both wild-type and β 2 AR-KO hearts after HFD feeding. Despite these metabolic defects, β 2 AR-KO myocytes and mice after HFD feeding display normalized contractile shortening and cardiac function, respectively, arguing that the improved cardiac function is largely independent of changes in systemic metabolism but may be caused, in part, by the currently characterized cardiac insulin-β 2 AR-arr-ERK pathway that induces PDE4D expression. A recent study shows that genetic ablation of GRK2 is effective in ameliorating adiposity and improving plasma levels of insulin, insulin signaling, and glucose intolerance in a HFD-induced diabetes animal model. 40, 41 We also observed attenuation of glucose intolerance in HFD mice after therapy with the GRK2 inhibitor paroxetine (online-only Data Supplement Figure III) , although not to the same extent. Thus, global improvement in insulin signaling could also contribute, in part, to the beneficial effects of GRK2 inhibition on cardiac function. Genetic and pharmacological inhibition of the cardiac insulin-β 2 ARarr pathway also attenuates the expression of cardiac GRK2 levels, which may contribute to improved cardiac function. Together these data suggest that adrenergic signaling and metabolic regulation may represent 2 independent therapeutic modalities to prevent or treat heart failure associated with obesity or type 2 DM.
Phosphodiesterases play essential roles in modulating ion channel activity, such as L-type calcium channels, ryanodine receptors and the serca2 pump, which controls EC coupling in cardiomyocytes. [42] [43] [44] [45] [46] [47] PDE3 and PDE4 are the major PDEs in both rodent and human hearts. 48 Recent studies indicated that the expression of PDEs is altered in diverse disease models, 49 potentially as an adaptation to early stage disease. In contrast, deletion of the PDE4D gene leads to spontaneous heart failure. 42 These observations suggest that phosphodiesterases play an essential role in maintaining a fine balance of tonic cAMP-PKA activity for tissue integrity and function in hearts. Here we show that in a model of insulin resistance and type 2 DM, activation of insulinsignaling pathways mediates the induction of PDE4D. Although myocytes isolated from mice after HFD feeding display impaired calcium signaling and contractile shortening, inhibition of PDE4 but not PDE3 completely rescued calcium signaling and contractile function after adrenergic stimulation. Taken together with earlier observations indicating hyperactivation of insulin signaling in failing human hearts 9 and the attenuation of heart failure when insulin signaling is reduced in a model of transverse aortic constriction, 7 these observations suggest that insulin-induced induction of PDE4 may be a central mechanism that contributes to heart failure. Further studies are needed to directly assess a role for PDE4 in obesity-and DM-associated cardiac dysfunction in vivo.
A detailed mechanistic understanding of the interactions between hyperinsulinemia and heart failure remains to be achieved. For example, the divergence between fibrosis, which was attenuated by inhibiting β 2 AR and GRK2 signaling, despite persistence of cardiac hypertrophy, underlies the complex interactions of these signaling pathways on distinct elements of cardiac remodeling. Thus, mechanisms linking cardiomyocyte ERK activation to the development of cardiac fibrosis in the context of metabolic disorders will be the focus of future investigations. Moreover, we have also previously shown that acute insulin treatment inhibits cardiac contractility by inducing G i -biased β 2 AR signaling in hearts. 17, 32 Whether this G i pathway contributes to insulin-induced transactivation of β 2 AR-arr-ERK, leading to cardiac dysfunction, remains to be examined. Furthermore, despite reduced IR levels in HFD hearts, the remaining IRs are still sufficient to activate ERK and Akt signaling in the face of persistent hyperinsulinemia. These signaling changes may lead to defects in cardiac metabolism or structural remodeling, including cardiac fibrosis. Indeed, although the focus of this study is on the relationship between ERK activation and PDE4D induction, which clearly might contribute to decreased cardiac contractility, it is possible that the cardiac fibrosis observed, although dependent on ERK signaling, could be independent of the induction of PDE4D.
These studies have important translational implications given the large number of individuals with the metabolic syndrome and the significant enrichment of heart failure among subjects with DM. 50 Hyperinsulinemia is a cardinal characteristic of patients with heart failure and also of those with the metabolic syndrome and type 2 DM, many of whom require high doses of insulin to achieve metabolic control. Thus, hyperinsulinemia by increasing the expression of PDE4 may exacerbate heart failure by limiting ventricular contractile reserve on the basis of reduced myocardial cAMP/PKA activity. Epidemiological and clinical observations have linked insulin treatment with increased mortality in patients with heart failure with diabetes. 21 Conversely, blocking the IRinduced β 2 AR-ERK signaling pathway either genetically or pharmacologically significantly alleviates the cardiac dysfunction (Figures 7 and 8) . In agreement, β blockade with either metoprolol 22 or carvedilol 23 reduces mortality in subjects with heart failure with DM, with the possibility that agents possessing β 2 selective inhibition could be somewhat more effective. 24 The present study suggests a specific role for the β 2 AR in hyperinsulinemia-induced cardiac dysfunction. Despite its property as an arrestinbiased ligand, carvedilol can attenuate insulin-induced ERK activation and PDE4 induction in vitro and in vivo. It is also possible that the β 1 AR could be activated as a consequence of the compensatory elevation of sympathetic drive, thereby indirectly contributing to cardiac dysfunction in hyperinsulinemic states. It remains to be determined whether the β 1 AR selective agent metoprolol is effective in ameliorating cardiac systolic and diastolic dysfunction. Paroxetine is an FDA-approved selective serotonin reuptake inhibitor that also inhibits GRK2. 36 Paroxetine was recently shown to be effective in treating myocardial infarction-induced heart failure, whereas another selective serotonin reuptake inhibitor, fluoxetine, did not. 37 Our data show that inhibition of GRK2 with paroxetine can also be effective in ameliorating cardiac dysfunction in HFD mice. Thus, in addition to providing new insights into the pathophysiology of heart failure in insulin-resistant states, our study provides a strong rationale for targeting β 2 AR-and GRK2-mediated signaling as an attractive therapeutic modality to prevent or treat heart failure associated with type 2 DM. 
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